InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Financial performance was strong with revenue, gross margin, and net income all showing significant improvements. However, the lack of specific guidance and vague responses in the Q&A section, particularly regarding new market expansions and supply chain challenges, introduce uncertainty. The absence of strategic initiatives and return plans further limits positive sentiment. Given these factors, the stock price is likely to remain stable, leading to a neutral prediction.
Key Financial Performance
Revenue The company reported revenue of $12.5 million for Q4 2025, representing a 15% increase year-over-year. This growth was attributed to strong sales in the European market and the successful launch of a new product line.
Gross Margin Gross margin improved to 68% in Q4 2025, up from 65% in the same period last year. The improvement was driven by cost efficiencies and a favorable product mix.
Operating Expenses Operating expenses rose to $8 million in Q4 2025, a 10% increase year-over-year. The rise was due to higher R&D investments and increased marketing efforts for the new product line.
Net Income Net income was reported at $1.2 million for Q4 2025, compared to $0.8 million in Q4 2024, marking a 50% increase. This was primarily due to higher revenue and improved gross margins.
Cash Flow The company generated $3 million in operating cash flow during Q4 2025, up from $2.5 million in the same period last year, reflecting better operational performance and working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Management highlighted that forward-looking statements are inherently uncertain and involve risks and uncertainties that may cause actual results to differ materially from expectations.
Regulatory risks: The company referred to risk factors described in its periodic reports, which likely include regulatory hurdles that could impact operations or strategic objectives.
Time-sensitive information: The company emphasized that the information shared is accurate only as of the date of the call, indicating potential risks of outdated or evolving circumstances affecting decision-making.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What were the key drivers of revenue growth this quarter?
A:The management attributed revenue growth to increased customer acquisition, higher average transaction values, and expansion into new markets.
Q:Can you provide more details on the new markets you expanded into?
A:The management mentioned entering three new regions but did not specify which ones or provide further details.
Q:What is the outlook for the next quarter?
A:The management expects continued growth but did not provide specific guidance or numerical targets.
Q:How is the company addressing supply chain challenges?
A:The management stated they are diversifying suppliers and increasing inventory levels but did not elaborate on the timeline or specific actions.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to questions about the specific new markets they expanded into, the numerical outlook for the next quarter, and detailed actions on supply chain challenges.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adam Maeder
CEO Director
Campbell Gilmartin
Director Lawless
Division EDT
Division Frank
Division Jeremy
EDT InspireMD
Frank Takkinen
Full Conference
Gleason Chief
Group LLC
InspireMD Full
Instructions replay
Jeremy Pearlman
LLC Adam
LLC Research
Maeder Piper
Marvin Slosman
Maxim Group
Officer Shane
Officer Webb
Pearlman Maxim
Piper Sandler
Research Division
Sandler Co
Shane Gleason
Slosman President
Webb Campbell
disclosure information
NSPR Transcript
InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call presents mixed signals. Financial performance was strong with revenue, gross margin, and net income all showing significant improvements. However, the lack of specific guidance and vague responses in the Q&A section, particularly regarding new market expansions and supply chain challenges, introduce uncertainty. The absence of strategic initiatives and return plans further limits positive sentiment. Given these factors, the stock price is likely to remain stable, leading to a neutral prediction.
InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript
Positive11-4
The company reported strong financial metrics with 39% YoY revenue growth and improved gross margins. Despite a net loss, the cash position is strong due to recent financing. The U.S. launch of CGuard Prime shows positive momentum with strong physician feedback. The Q&A highlighted positive sentiment and growth expectations, although management avoided specific margin guidance. Overall, the earnings call suggests a positive short-term outlook, with expected growth in the U.S. market and improved margins.
InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call indicates a challenging financial position with increased net losses and operating expenses, alongside decreased gross margins. While there is positive momentum with the U.S. launch of CGuard Prime, adoption is gradual, and management's lack of specific guidance raises concerns. The Q&A section highlighted uncertainties in timelines and market strategies. Despite some positive developments, the overall sentiment is negative due to financial strain and unclear future prospects.
InspireMD, Inc. (NASDAQ:NSPR) Q1 2025 Earnings Call Transcript
Unknown5-10
The earnings call reveals several concerns: missed earnings expectations, increased operating expenses, and a significant net loss. The lack of forward-looking revenue guidance and the delay in FDA approval for CGuard Prime add to uncertainties. Despite positive clinical trial data and a strong sales force expansion, these factors, combined with competitive pressures and supply chain challenges, create a negative outlook. The absence of share repurchase or dividend programs further limits investor appeal. Overall, the sentiment is negative, with potential for a stock price decline in the range of -2% to -8%.
NSPR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
